Dr. Scott Gottlieb, former FDA chief in the Trump administration, told CNBC on Friday that White House doctors are “probably considering” whether to give President Donald Trump remdesivir, Gilead Sciences’ the antiviral drug approved for treating Covid-19 under emergency use authorization.
“Remdesivir is indicated for hospitalized patients. But there is thinking that it probably improves outcomes earlier it is introduced in the course of the disease,” Gottlieb said in a “Squawk Box” interview.
The main question on how to proceed now that the president, first lady Melania Trump and White House advisor Hope Hicks tested positive for coronavirus is whether they are exhibiting symptoms, Gottlieb said.
Trump, 74, tweeted at 12:54 a.m. ET that he and the 50-year-old first lady tested positive for Covid-19, hours after the president said he would begin a quarantine process after the 31-year-old Hicks’ positive test.
The president and first lady are “both well” at the moment, according to a statement from White House physician Dr. Sean Conley, released shortly after the president’s tweet. Conley also wrote that he expects Trump to “continue carrying out his duties without disruption while recovering.”
“They all have a good chance of doing well. [Trump] was previously in good health by all reports and will get excellent care,” Gottlieb said.
However, Gottlieb said, “The president is in a high-risk group simply by virtue of his age, 74. He’s also reported to be overweight.”